search
Back to results

Vitamin D Deficiency in Adolescent Girls

Primary Purpose

Healthy, Vitamin D Deficiency

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
ergocalciferol
placebo pill
Sponsored by
Massachusetts General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Healthy focused on measuring FGF23, FGF-23, vitamin D, vitamin D deficiency, insulin resistance, Healthy volunteers

Eligibility Criteria

9 Years - 18 Years (Child, Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • healthy girls aged 9-18 years

Exclusion Criteria:

  • significant cardiac, hepatic, oncologic, or psychiatric disease
  • a history of malabsorption, kidney stones, hypoparathyroidism, or growth hormone deficiency
  • pregnancy
  • diabetes mellitus
  • BMI>/= 99th percentile for age and sex
  • fracture within the preceding 3 months
  • hypogonadism (no pubertal development by age 12, absence of menarche by age 14)
  • serum calcium <8 mg/dl or >11 mg/dl
  • radiographic evidence of rickets
  • use of medications know to affect serum phosphate levels including phosphate-binding antacids, sodium etidronate, calcitonin, excessive doses of vitamin D (>1000 units per day), excessive doses of vitamin D (>20,000 units/day), calcitriol, growth hormone, or anti-convulsants.
  • use of hormonal birth control

Sites / Locations

  • Massachusetts General Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Ergocalciferol

Placebo

Arm Description

Weekly ergocalciferol for 16 weeks

Placebo pill. Note that all subjects in this arm will receive vitamin D repletion at the conclusion of the study.

Outcomes

Primary Outcome Measures

change in FGF23 level with vitamin D repletion

Secondary Outcome Measures

change in bone turnover markers with vitamin D repletion
change in mineral metabolism factors with vitamin D repletion
change in insulin sensitivity with vitamin D repletion

Full Information

First Posted
August 11, 2010
Last Updated
November 1, 2013
Sponsor
Massachusetts General Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01180946
Brief Title
Vitamin D Deficiency in Adolescent Girls
Official Title
Vitamin D Deficiency in Adolescent Girls
Study Type
Interventional

2. Study Status

Record Verification Date
November 2013
Overall Recruitment Status
Completed
Study Start Date
September 2010 (undefined)
Primary Completion Date
April 2013 (Actual)
Study Completion Date
April 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Fibroblast growth factor 23 (FGF23) is a newly discovered hormone which regulates phosphate and vitamin D levels. In this study, we are looking at what the normal levels of FGF23 are in adolescent girls and how these levels vary with other hormonal measurements. We will also be looking at whether vitamin D supplementation in adolescents who are deficient in vitamin D alters the levels of FGF23 and other factors including insulin resistance.
Detailed Description
Fibroblast growth factor 23 (FGF23) is a newly discovered hormone. Its primary function is to regulate phosphate metabolism, which it does both by directly regulating phosphate excretion through the kidney as well as by regulating vitamin D activity. What controls FGF23 levels is still under investigation; potential factors include dietary phosphate intake and vitamin D levels. In this pilot study, we aim to investigate what the normal levels of FGF23 are in healthy girls and how these are related to other measurements of bone and mineral metabolism. Since vitamin D deficiency is very common in healthy girls, we expect a subset of the subjects in this study to be vitamin D deficient. We will then randomize these girls to vitamin D repletion or placebo and follow changes in FGF23 levels. Vitamin D deficiency has also been implicated in insulin resistance which is a precursor to diabetes. We will therefore also look at changes in insulin resistance with vitamin D repletion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy, Vitamin D Deficiency
Keywords
FGF23, FGF-23, vitamin D, vitamin D deficiency, insulin resistance, Healthy volunteers

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
90 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ergocalciferol
Arm Type
Active Comparator
Arm Description
Weekly ergocalciferol for 16 weeks
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo pill. Note that all subjects in this arm will receive vitamin D repletion at the conclusion of the study.
Intervention Type
Dietary Supplement
Intervention Name(s)
ergocalciferol
Other Intervention Name(s)
vitamin D
Intervention Description
ergocalciferol (a dietary form of vitamin D). 50,000 units by mouth once a week for 16 weeks.
Intervention Type
Other
Intervention Name(s)
placebo pill
Intervention Description
placebo pill once weekly for 16 weeks. At the end of the study, subjects in this arm will receive vitamin D repletion
Primary Outcome Measure Information:
Title
change in FGF23 level with vitamin D repletion
Time Frame
baseline and 16 weeks
Secondary Outcome Measure Information:
Title
change in bone turnover markers with vitamin D repletion
Time Frame
baseline and 16 weeks
Title
change in mineral metabolism factors with vitamin D repletion
Time Frame
baseline and 16 weeks
Title
change in insulin sensitivity with vitamin D repletion
Time Frame
baseline and 16 weeks

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
9 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: healthy girls aged 9-18 years Exclusion Criteria: significant cardiac, hepatic, oncologic, or psychiatric disease a history of malabsorption, kidney stones, hypoparathyroidism, or growth hormone deficiency pregnancy diabetes mellitus BMI>/= 99th percentile for age and sex fracture within the preceding 3 months hypogonadism (no pubertal development by age 12, absence of menarche by age 14) serum calcium <8 mg/dl or >11 mg/dl radiographic evidence of rickets use of medications know to affect serum phosphate levels including phosphate-binding antacids, sodium etidronate, calcitonin, excessive doses of vitamin D (>1000 units per day), excessive doses of vitamin D (>20,000 units/day), calcitriol, growth hormone, or anti-convulsants. use of hormonal birth control
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sherri-Ann Burnett-Bowie, MD, MPH
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
19419295
Citation
Burnett-Bowie SM, Henao MP, Dere ME, Lee H, Leder BZ. Effects of hPTH(1-34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men. J Bone Miner Res. 2009 Oct;24(10):1681-5. doi: 10.1359/jbmr.090406.
Results Reference
background
PubMed Identifier
17157573
Citation
Burnett-Bowie SM, Mendoza N, Leder BZ. Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men. Bone. 2007 Apr;40(4):913-8. doi: 10.1016/j.bone.2006.10.016. Epub 2006 Dec 8.
Results Reference
background
PubMed Identifier
16869716
Citation
Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res. 2006 Aug;21(8):1187-96. doi: 10.1359/jbmr.060507.
Results Reference
background
PubMed Identifier
28323960
Citation
Mitchell DM, Juppner H, Burnett-Bowie SM. FGF23 Is Not Associated With Age-Related Changes in Phosphate, but Enhances Renal Calcium Reabsorption in Girls. J Clin Endocrinol Metab. 2017 Apr 1;102(4):1151-1160. doi: 10.1210/jc.2016-4038.
Results Reference
derived

Learn more about this trial

Vitamin D Deficiency in Adolescent Girls

We'll reach out to this number within 24 hrs